115563
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
杨梅酮与阿霉素的协同作用克服卵巢癌的化疗耐药性：来自体外和体内模型的临床前见解
Authors Wu R, Bostani A, Wang J
Received 14 September 2025
Accepted for publication 16 December 2025
Published 8 January 2026 Volume 2026:18 567591
DOI https://doi.org/10.2147/CMAR.S567591
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Seema Singh
Ruihua Wu,1 Amirabas Bostani,2 Junmei Wang3
1Department of Obstetrics and Gynecology, Xi’an People’s Hospital (Xi’an Fourth Hospital), Xi’an, 710000, People’s Republic of China; 2Department of Biology, Science & Research Institute, Islamic Azad University, Tehran, Iran; 3Department of Obstetrics and Gynecology, XD Group Hospital, Xi’an, 710000, People’s Republic of China
Correspondence: Junmei Wang, Department of Obstetrics and Gynecology, XD Group Hospital, Xi’an, 710000, People’s Republic of China, Tel +86 3319206720, Email wjm980015@sina.com
Background: Epithelial ovarian cancer (EOC) remains highly lethal due to late-stage diagnosis and chemoresistance, necessitating strategies to enhance conventional therapies like doxorubicin (DOX) while mitigating toxicity. This study evaluated morin, a flavonoid, as an adjunct to DOX in chemoresistant EOC models.
Methods: In vitro, DOX-resistant OVCAR-3-DR, OVCAR-3, and A2780 cells were treated with DOX, morin, or their combination. Synergy was assessed via MTT and apoptosis assays, alongside autophagy and cell cycle markers. In vivo, OVCAR-3-DR xenograft mice were divided into Sham, DOX (5 mg/kg), morin (15 and 30 mg/Kg), and combination groups. Tumor volume, apoptosis (BCL-2, caspase-3/9), autophagy (LC3, ATG5, Beclin-1), cell cycle regulators (Cyclin A2/D1), and oxidative stress (SOD, CAT, GPx, GR, GSH, MDA) were analyzed.
Results: Findings demonstrated significant synergistic cytotoxicity, with a combination index (CI) of 0.72, and enhanced apoptosis. Combination therapy suppressed Cyclin A2/D1, upregulated autophagy markers (, and reduced oxidative stress. In vivo, DOX+Morin30 reduced tumor volume synergistically (p< 0.001) without systemic toxicity (stable body weight).
Conclusion: Morin synergizes with DOX by modulating apoptosis, autophagy, cell cycle, and oxidative stress, overcoming chemoresistance while reducing toxicity. These findings position morin as a promising, orally bioavailable adjunct worthy of further clinical investigation for optimizing DOX therapy in refractory EOC.
Keywords: ovarian neoplasms, flavonoids, drug resistance, apoptosis, autophagy, xenograft model antitumor assays
1Department of Obstetrics and Gynecology, Xi’an People’s Hospital (Xi’an Fourth Hospital), Xi’an, 710000, People’s Republic of China; 2Department of Biology, Science & Research Institute, Islamic Azad University, Tehran, Iran; 3Department of Obstetrics and Gynecology, XD Group Hospital, Xi’an, 710000, People’s Republic of China
Correspondence: Junmei Wang, Department of Obstetrics and Gynecology, XD Group Hospital, Xi’an, 710000, People’s Republic of China, Tel +86 3319206720, Email wjm980015@sina.com
Background: Epithelial ovarian cancer (EOC) remains highly lethal due to late-stage diagnosis and chemoresistance, necessitating strategies to enhance conventional therapies like doxorubicin (DOX) while mitigating toxicity. This study evaluated morin, a flavonoid, as an adjunct to DOX in chemoresistant EOC models.
Methods: In vitro, DOX-resistant OVCAR-3-DR, OVCAR-3, and A2780 cells were treated with DOX, morin, or their combination. Synergy was assessed via MTT and apoptosis assays, alongside autophagy and cell cycle markers. In vivo, OVCAR-3-DR xenograft mice were divided into Sham, DOX (5 mg/kg), morin (15 and 30 mg/Kg), and combination groups. Tumor volume, apoptosis (BCL-2, caspase-3/9), autophagy (LC3, ATG5, Beclin-1), cell cycle regulators (Cyclin A2/D1), and oxidative stress (SOD, CAT, GPx, GR, GSH, MDA) were analyzed.
Results: Findings demonstrated significant synergistic cytotoxicity, with a combination index (CI) of 0.72, and enhanced apoptosis. Combination therapy suppressed Cyclin A2/D1, upregulated autophagy markers (, and reduced oxidative stress. In vivo, DOX+Morin30 reduced tumor volume synergistically (p< 0.001) without systemic toxicity (stable body weight).
Conclusion: Morin synergizes with DOX by modulating apoptosis, autophagy, cell cycle, and oxidative stress, overcoming chemoresistance while reducing toxicity. These findings position morin as a promising, orally bioavailable adjunct worthy of further clinical investigation for optimizing DOX therapy in refractory EOC.
Keywords: ovarian neoplasms, flavonoids, drug resistance, apoptosis, autophagy, xenograft model antitumor assays